DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Analyzing the Potential of AAV2-GDNF Gene Therapy in Parkinson’s Disease Treatment: Insights from Phase Ib Trial Data
AB-1005 represents a pioneering gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene directly into the brain. This innovative technique allows for precise and sustained expression of GDNF, offering promising therapeutic potential for conditions like Parkinson’s disease characterized by the degeneration of midbrain dopaminergic neurons. GDNF, a member of the transforming growth factor-β superfamily, has demonstrated remarkable neuroprotective effects in preclinical studies. By promoting the survival and differentiation of dopaminergic neurons in the midbrain, GDNF holds the promise…
LIBERVANT Buccal Film: Pioneering Pediatric Epilepsy Treatment Advancements
LIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope, offering convenient alternatives to existing device-based products, for managing acute repetitive seizure emergencies in young patients. LIBERVANT utilizes "fast-melt strips" for "buccal delivery of diazepam, offering promises to rewrite the narrative of acute repetitive seizure emergencies, ushering in an era of renewed optimism and therapeutic advancement. At the 76th Annual Meeting of the American Academy of Neurology (AAN) 2024 in Denver from April 13 to 18, Aquestive Therapeutics presented an abstract for the crossover study data evaluating the…
Analyzing ABBV-951 for Parkinson’s Disease: A Promise in Addressing Motor Fluctuations and Enhancing Quality of Life
ABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's disease by providing continuous subcutaneous delivery of carbidopa and levodopa prodrugs, aiming to address motor fluctuations more effectively than oral medication. Leveraging its small molecule design and targeted action on dopamine receptors, ABBV-951 presents a promising approach to managing the challenging symptoms of Parkinson's disease, including tremors, muscle rigidity, and impaired movement, offering potential improvements in patients' quality of life. Parkinson's disease (PD) poses significant challenges as it progresses, with motor fluctuations and dyskinesias often…